Pacer Advisors
SMMT icon

Pacer Advisors’s Summit Therapeutics SMMT Stock Holding History

Pacer Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50K Buy
+3,451
New +$61.2K ﹤0.01% 2041
2024
Q3 		– Sell
-944
Closed -$7.36K – 2683
2024
Q2 		$7.36K Sell
944
-2,085
-69% -$11.3K ﹤0.01% 3594
2024
Q1 		$12.5K Buy
+3,029
New +$12K ﹤0.01% 3508

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Pacer Advisors's SMMT Position: Q2 2026 in Review

Pacer Advisors opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 3,451 shares worth $50K. The stake represents ﹤0.01% of the portfolio and ranks #2041 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in SMMT as recently as Q2 2024.

Pacer Advisors first reported a position in SMMT in Q1 2024 and has held it in 3 quarters since. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Pacer Advisors held 3,451 shares of Summit Therapeutics worth $50K as of Q2 2026.
  • Summit Therapeutics was a new Pacer Advisors position in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2041 holding.
  • Pacer Advisors first reported a position in Summit Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.